Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]
Please note this appraisal has now been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process STA Standard
ID number 657
Referral date 01 November 2014

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Associate Director: TBC
Communications manager: TBC
Project manager:

TBC

Technical Advisor: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 January 2024 Discontinued. Please note this appraisal has now been discontinued.
27 January 2015 Following on from advice received from the company, the dates for this appraisal will be confirmed once regulatory approval timelines are established.
27 January 2015 Scoped as part of Batch 37

For further information on our processes and methods, please see our CHTE processes and methods manual